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Abstract
Background: Curcumin inhibits the growth of pancreatic cancer tumor xenografts in nude mice; however, the mechanism
of action is not well understood. It is becoming increasingly clear that RNA binding proteins regulate posttranscriptional
gene expression and play a critical role in RNA stability and translation. Here, we have determined that curcumin modulates
the expression of RNA binding protein CUGBP2 to inhibit pancreatic cancer growth.
Methodology/Principal Findings: In this study, we show that curcumin treated tumor xenografts have a significant
reduction in tumor volume and angiogenesis. Curcumin inhibited the proliferation, while inducing G2-M arrest and
apoptosis resulting in mitotic catastrophe of various pancreatic cancer cells. This was further confirmed by increased
phosphorylation of checkpoint kinase 2 (Chk2) protein coupled with higher levels of nuclear cyclin B1 and Cdc-2. Curcumin
increased the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) mRNA, but protein
levels were lower. Furthermore, curcumin increased the expression of RNA binding proteins CUGBP2/CELF2 and TIA-1.
CUGBP2 binding to COX-2 and VEGF mRNA was also enhanced, thereby increasing mRNA stability, the half-life changing
from 30 min to 8 h. On the other hand, silencer-mediated knockdown of CUGBP2 partially restored the expression of COX-2
and VEGF even with curcumin treatment. COX-2 and VEGF mRNA levels were reduced to control levels, while proteins levels
were higher.
Conclusion/Significance: Curcumin inhibits pancreatic tumor growth through mitotic catastrophe by increasing the
expression of RNA binding protein CUGBP2, thereby inhibiting the translation of COX-2 and VEGF mRNA. These data
suggest that translation inhibition is a novel mechanism of action for curcumin during the therapeutic intervention of
pancreatic cancers.
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Introduction
Despite the advances in molecular pathogenesis, pancreatic
cancer remains a major unsolved health problem in the United
States [1]. Pancreatic cancer is a rapidly invasive, metastatic
tumor, which is resistant to standard therapies [2,3]. At present,
single agent based chemotherapy (e.g. Gemcitabine) is the
mainstay treatment for metastatic adenocarcinoma of pancreas.
Gemcitabine treatment has a tumor response rate of below 10%;
similarly none of the available current chemotherapeutic agents
have an objective response rate of over 10% [4,5]. More recently,
drug combinations with gemcitabine are also being examined, but
it is too early to tell if they are clinically superior. Nevertheless, the
magnitude of this problem mandates the need for novel
therapeutic agents.
Epidemiological studies suggest that diet plays a major role in
the prevention of many cancers. Curcumin, an active ingredient in
the spice turmeric, has shown anti-tumor effects in preclinical
studies [6,7]. Anti-tumor properties of curcumin include inhibition
of tumor growth and induction of apoptosis [8,9,10,11,12,
13,14,15,16]. Pilot Phase I clinical trials have shown that curcumin
is safe even when consumed at a daily dose of 12 g for 3 months
[17,18,19]. A most recent phase I/II study demonstrated that
combination therapy using 8 g oral curcumin daily with
gemcitabine was safe and feasible for patients with pancreatic
cancer warranting further investigation into its efficacy [20].
The anti-tumor properties of curcumin have been attributed, at
least in part, to its ability to inhibit the expression and activity of
cyclooxygenase-2 (COX-2) [21,22]. It is a rate-limiting enzyme in
the arachidonic acid to prostaglandin synthesis pathway. The
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cancers. In pancreatic cancers, COX-2 overexpresssion is
associated with inhibition of apoptosis, increased tumor invasive-
ness, and promotion of angiogenesis. The CELF (CUGBP-ETR3-
like factors) family of RNA binding proteins is composed of six
members that are involved in various cellular processes including
mRNA splicing, editing, stability and translation [23]. One of the
members, CUGBP2 (also known as CELF2, ETR3, BRUNOL2,
Napor2) is expressed ubiquitously, albeit at higher levels in muscle
cells [24,25]. In previous studies, we have demonstrated that when
CUGBP2 is overexpressed, the cells undergo mitotic catastrophe
[26,27]. We have also demonstrated that CUGBP2 can bind to
AU-rich sequences in the 39untranslated region of COX-2 mRNA
and increase the stability of the mRNA while inhibiting its
translation [28]. HuR, a related RNA binding protein with
structural similarity to CUGBP2 on the other hand is implicated in
increasing COX-2 mRNA stability and enhancing its translation
by binding to the same AU-rich sequence elements [29]. A third
RNA binding protein that functions as a post-transcriptional
regulator of gene expression by recognizing U-rich sequence in the
RNA is TIA-1 (T-cell-restricted intracellular antigen-1). TIA-1 has
been shown to inhibit mRNA translation in conditions of
environmental stress [30,31]. In this article, we have determined
the effect of curcumin on the expression of RNA binding proteins
in pancreatic cancer cells.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
Institutional Animal Care and Use Committee (IACUC) (Proto-
col#07-009) of University of Oklahoma Health Sciences Center.
Cells and Reagents
AsPC-1, MiaPaCa-2, Panc-1, BxPC-3 human and Pan02
mouse pancreatic cancer cells (all from American Type Culture
Collection, Manassas, VA) were grown in RPMI 1640 containing
10% heat inactivated fetal bovine serum (Sigma Chemical Co, St.
Louis, MO) and 1% antibiotic-antimycotic solution (Mediatech
Inc, Herndon, VA) at 37uC in a humidified atmosphere of 5%
CO2. Curcumin was purchased from LKT Laboratories, St Paul,
MN.
Proliferation and Apoptosis assays
To assess proliferation, cells were seeded on to 96 well plates
and grown overnight. The cells were then treated with increasing
doses of curcumin in RPMI 1640 media containing 10% FBS.
Analysis of cell proliferation was performed by enzymatic assay
[32]. For apoptosis, caspase 3/7 activity was measured using the
Apo-one Homogeneous Caspase-3/7 Assay kit (Promega, Madi-
son, WI).
Colony formation assay
Briefly, 6 well dishes were seeded with 500 viable cells and
allowed to grow for 24 h. The cells were then incubated in the
presence or absence of various concentrations of curcumin for up
to 48 h. The curcumin-containing medium was then removed,
and the cells were washed in PBS and incubated for an additional
10 d in complete medium. Each treatment was done in triplicate.
The colonies obtained were washed with PBS and fixed in 10%
formalin for 10 min at room temperature and then washed with
PBS followed by staining with hematoxylin. The colonies were
counted and compared with untreated cells.
Cell cycle analyses
Cells were treated with curcumin for 12 h and 24 h, and
subsequently trypsinized and suspended in phosphate buffered
saline (PBS). Single-cell suspensions were fixed using 70% ethanol
for 2 h, and subsequently permeabilized with PBS containing
1 mg/ml propidium iodide (Sigma-Aldrich), 0.1% Triton X-100
(Sigma-Aldrich) and 2 mg DNase-free RNase (Sigma-Aldrich) at
room temperature. Flow cytometry was done with a FACSCalibur
analyzer (Becton Dickinson, Mountain, View, CA), capturing
50,000 events for each sample. Results were analyzed with ModFit
LT
TM software (Verity Software House, Topsham, ME).
Real Time Reverse-Transcription Polymerase Chain
Reaction Analysis
Total RNA isolated from MiaPaCa-2, Pan02 cells and tumor
xenografts using TRIZOL reagent was reverse transcribed with
Superscript II reverse transcriptase in the presence of random
hexanucleotide primers (all from Invitrogen, Carlsbad, CA).
Complementary DNAs were then used for Real time PCR using
Jumpstart Taq DNA polymerase (Sigma Chemical Co, St. Louis,
MO) and SYBR Green nucleic acid stain (Molecular Probes,
Eugene, OR). Crossing threshold values for individual genes were
normalized to b-Actin. Changes in mRNA expression were
expressed as fold change relative to control. Primers used in this
study were as follows: b-Actin: 59-GCTGATCCACATCT-
GCTGG-39 and 59-ATCATTGCTCCTCCTCAGCG-39; CO-
X-2: 59-GAATCATTCACCAGGCAAATTG-39 and 59-TCTG-
TACTGCGGGTGGAACA-39; VEGF: 59-AGCGCAAGAA-
ATCCCGGTA-39 and 59-TGCTTTCTCCGCTCTGAGC-39;
HuR: 59-GTGAACTACGTGACCGCGAA-39and 59-GACTG-
GAGCCTCAAGCCG-39; CUGBP2: 59-TGCTTCAACCCCC-
AACTCC-39 and 59-GTCCTTGCAGAGTCCCGAGA-39; TIA-
1: 59-ACCCATCTGTTGAATGGCGT-39and 59- GGCAA-
CAGGAAAGTCTAAGGGAT-39; Cyclin D1: 59-AATGAC-
CCCGCACGATTTC-39 and 59-TCAGGTTCAGGCCTTG-
CAC-39.
RNA Stability assay
Cells were treated with curcumin for 2 h. Actinomycin-D
(10 mg/ml final concentration), a potent inhibitor of mRNA
synthesis was added to the cells and total mRNA was extracted at
0–8 h. RNA was subjected to Real time PCR as described above.
Data is presented as relative to control cells, at the time of addition
of actinomycin D.
Western Blot Analysis
Cell lysates were subjected to polyacrylamide gel electrophoresis
and blotted onto Immobilin polyvinylidene difluoride membranes
(Millipore, Bedford, MA). Antibodies were purchased from Cell
Signaling Technology (Beverly, MA), Abcam Inc (Cambridge,
MA) and Santa Cruz Biotechnology Inc (Santa Cruz, CA) and
specific proteins were detected by the enhanced chemilumines-
cence system (Amersham Pharmacia Biotech, Piscataway, NJ).
Immunoprecipitation
For immunoprecipitation, the cells were fixed with 1% formalin.
Lysates were prepared and immunoprecipitated with anti-
CUGBP2 antibody. The pellet and supernatant were subsequently
incubated at 70uC for 1 h to reverse the cross-links, and RNA was
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VEGF mRNA levels.
siRNA
Sequence targeting the CUGBP2 mRNA 59-GCAAACCUUA-
CUGAUCCUA-39 (Accession mumber ns. NM_001025076) and
a scrambled control siRNA not matching any of the human genes
were obtained from Ambion Inc, Texas, USA and transfected with
siPORT transfection reagent (Ambion).
Pan02 xenograft tumors
Five-week-old male athymic nude mice purchased from Jackson
Laboratories were utilized for in vivo experiments. The mice were
maintained with water and standard mouse chow ad libidum that is
used in protocols approved by the University’s Animal Studies
Committee. Animals were injected with 1610
6 Pan02 cells in the
left and right flank and allowed to form xenografts. One week
following planting the cells and after observing the presence of a
palpable tumor, curcumin (200 mg/kg body weight) in 5% Na2
HCO3 buffer alone was administered intraperitoneally daily for
23 d. Tumor size was measured weekly. At the end of treatment
the animals were sacrificed, and the tumors were removed,
weighed, and prepared for use in histology (hematoxylin & eosin,
COX-2, VEGF, and CD31) and gene expression studies.
Immunocytochemistry and immunohistochemistry
Cells were plated on to coverslip and allowed to grow for 24 h.
The cells were then fixed with 10% buffered formalin for 10 min
and subsequently washed with PBS. The cells were then
permeabilized with PBS containing 0.5% Triton X-100 for
10 min. The coverslips were incubated with rabbit anti-cyclin
B1 (Santa Cruz Biotechnologies, Santa Cruz, CA) and rabbit anti-
Cdc2 antibodies (Abcam Inc, Cambridge, MA), followed by
biotinylated anti-rabbit IgG. The slides were further processed
using Vectastatin ABC kit (Vector Laboratories, Burlingame, CA)
followed by DAB staining.
Tissues embedded in paraffin were cut to a section of 4 mM,
deparaffinized and treated with citrate buffer. Then they were
blocked with Avidin/Biotin for 20 min. The slides were incubated
with anti-COX-2 or VEGF or CD31 or HuR or CUGBP2 or
TIA-1 or Cyclin D1 for overnight at 4uC. Next the slides were
treated with the secondary antibody such as HRP- goat anti-rabbit
for subsequent COX-2, VEGF, HuR, CUGBP2, TIA-1, and
Cyclin D1 staining. For CD31staining goat anti-rat HRP was
utilized. Each secondary antibody was incubated for one hour and
then developed with DAB (Sigma Aldrich). Finally, the slides were
counterstained with hematoxylin.
Statistical analysis
All values are expressed as the mean 6 SEM. Data was
analyzed using a unpaired 2-tailed t test. A P value of less than
0.05 was considered statistically significant.
Results
Curcumin inhibits tumor growth of Pan02 tumor
xenografts and angiogenesis
To begin evaluating the role of curcumin on tumor proliferation
in vivo, we examined the ability of curcumin to suppress the growth
of mouse pancreatic cancer cell xenografts in nude mice.
Pancreatic cancer cell induced xenograft tumors were allowed to
develop and grow to a size of 200 mm
3 following which curcumin
was administered intraperitoneally for three weeks daily. Curcu-
min significantly inhibited the growth of the tumor xenografts
(Fig. 1A). The excised tumors from control animals ranged from
700 to 800 mg while those treated with curcumin weighed less
than 400 mg (Fig. 1B). In addition, tumor volume was significantly
decreased (Fig. 1A). There was no apparent change in liver weight,
spleen weight, or body weight in the animals (data not shown).
These data imply that curcumin is a potent therapeutic agent to
treat pancreatic cancers and is relatively non-toxic to the mice. We
also determined the effect of curcumin on tumor vascularization
by staining for the endothelial specific antigen CD31. As shown in
Figure 1C, curcumin treatment significantly lowered CD31
staining and obliterated the tumor vessels suggesting decreased
angiogenesis. We also calculated the microvessel density and found
it to be significantly decreased following curcumin treatment
(Fig. 1D).
Curcumin inhibits pancreatic cancer cell growth
To determine the mechanism of curcumin-mediated growth
arrest, we studied pancreatic cancer cells in vitro. For this we used
five different cultured cell lines MiaPaCa-2, Panc-1, AsPC-1,
BxPC-3 and Pan02. Curcumin significantly suppressed the
proliferation of pancreatic cancer cell lines MiaPaCa-2, Pan02,
AsPC-1, BxPC-3 and Panc-1 in a dose and time dependent
manner. This anti-proliferation effect on tumor cells was seen
within a 24 h period, which continued to significantly increase
over the next 72 h (Fig. 2A). To determine the long-term effect of
curcumin treatment, cells were treated with 30mM curcumin for
24 h, following which the cells were allowed to grow in normal
media. Curcumin treatment suppressed colony formation in all
pancreatic cancer cell lines (Fig. 2B), suggesting that curcumin’s
effects on the tumor cells was irreversible. Cyclin D1 is a cell cycle
regulatory protein that regulates the G1 to S-phase transition of
the cell cycle and functions as a cofactor for several transcription
factors [33]. Cyclin D1 overexpression has been linked to the
development and progression of cancer [34]. In both MiaPaCa-2
and Pan02 cells, curcumin treatment resulted in reduced cyclin D1
expression at 24 h (Fig. 2C, D). Furthermore, cyclin A2, which
regulates S/G2 progression, was downregulated potentially
slowing progression of cells out of S phase (data not shown).
Curcumin induces G2-M cell cycle arrest before mitotic
catastrophe
We next determined whether curcumin affects cell cycle
progression and the consequence of this effect. Curcumin induced
growth arrest of the MiaPaCa-2 within 24 h at the G2M stage
(Fig. 3A). Similar results were observed in Panc-1 and Pan02 cells
(data not shown). Curcumin is known to induce apoptosis in
variety of cancer cells. Caspase-3 and 7 are key effector molecules
known to induce apoptosis in variety of cancer cells by amplifying
the signal from initiator caspases, such as caspase 8 or caspase 10
[35,36]. Capsase 3 and 7 were increased within 24 h in the
MiaPaCa-2 cells line treated with curcumin suggesting the
induction of apoptosis (Fig. 3B). Western blot analyses of
MiaPaCa-2 and Pan02 cell lysates demonstrated a significant
increase in the activated caspase-3 in curcumin treated cells
(Fig. 3B inset). These data suggest that curcumin treated tumor
cells were undergoing apoptosis. To determine whether an arrest
at the G2 phase or lack of progression to mitosis is contributing to
the higher level of cells seen in G2M phase, we assessed the
expression, and localization of cyclin B1 and the serine/thereonine
kinase Cdc-2. Cyclin B1/Cdc-2 complex plays a significant role in
the G2M phase transition of cell cycle. To induce mitosis, cyclin
B1 and Cdc-2 heterodimerize and localize to the nucleus, which in
turn activates the enzymes that regulates chromatin condensation,
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reorganization [37,27]. Immunocytochemical analysis demon-
strated significantly higher nuclear levels of both cyclin B1 and
Cdc-2 in curcumin treated cells suggesting that curcumin treated
cells were undergoing mitotic catastrophe (Fig. 3C). In addition to
this, western blot analysis demonstrated increased expression of
both cyclin B1 and Cdc-2 in curcumin treated cells and
phosphorylation of Chk2 kinase in both MiaPaCa-2 cells in
culture and the Pan02 tumor xenograft tissues (Fig. 3D). Given
that the cells were undergoing apoptosis at the same time that they
were in G2-M arrest, suggests that curcumin induces the cells to
undergo mitotic catastrophe.
Curcumin inhibits COX-2 and VEGF expression while
inducing CUGBP2 and TIA-1
COX-2 plays a significant role in carcinogenesis, including
increased invasiveness, promotion of angiogenesis and resistance
to apoptosis [38]. We therefore determined its expression in tumor
xenografts. Real time PCR analyses demonstrated that COX-2
mRNA expression was significantly lower in curcumin treated
tumor xenografts when compared to the control tumors (Fig. 4A).
This was further confirmed by western blot and immunohisto-
chemistry analyses, where lower levels of COX-2 protein were
observed in the curcumin-treated tissues (Fig. 4B,C). Prostaglan-
dins and the other tumor promoters are known to induce the
Figure 1. Curcumin inhibits growth of Pan02 tumor xenografts. (A) Nude mice carrying Pan02 cell tumor xenografts in the flanks were
administered curcumin intraperitoneally for 3 weeks. There was a significant reduction in tumor size from curcumin-treated animals when compared
to untreated controls (*p,0.05). (B) Curcumin treatment resulted in significantly lower tumor weight when compared to controls (*p,0.05). (C)
Tumor sections were stained for CD31, an endothelial cell specific surface marker and with hematoxylin and eosin (H&E). A representative figure is
presented showing significant reduction in microvessels. (D) The number of microvessels in the tumor tissues were counted in 12 high power fields
and averaged. Data shows that microvessel density was significantly reduced in the xenografts of curcumin treated animals (*p,0.05).
doi:10.1371/journal.pone.0016958.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16958Figure 2. Curcumin inhibits pancreatic cancer cell growth. (A) Curcumin inhibits proliferation of pancreatic cancer cells. MiaPaCa-2, Pan02,
AsPC-1 and BxPC-3 cells were incubated with curcumin (1–50 mM) for up to 72 h. Cell proliferation was analyzed using hexosaminidase enzyme
activity. Curcumin treatment resulted in a significant dose-and time-dependent decrease in cell proliferation in all the cells when compared with
untreated controls. (B) Curcumin inhibits colony formation. MiaPaCa-2 and Pan02 cells were incubated with 30 mM of curcumin for 24 h and colonies
were allowed to form by incubating in regular media containing 10% FBS for an additional 10 d. Treatment with curcumin inhibited colony
formation. A representative of three independent experiments is shown. (C) Expression of cyclin D1 is suppressed at 24 h. RNA from MiaPaCa-2 and
Pan02 cells incubated with 30 mM curcumin were subjected to Real time PCR for cyclin D1 mRNA expression. There was significant suppression of the
mRNA at 24 h but not at 12 h (*p,0.05). (D) Lysates from MiaPaCa-2 or Pan02 incubated with 30 mM curcumin were analyzed by western blotting for
cyclin D1 expression levels. Curcumin treatment inhibits cyclin D1 mRNA and protein expression.
doi:10.1371/journal.pone.0016958.g002
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16958Figure 3. Curcumin induces mitotic catastrophe. A) Cell cycle profiles of MiaPaCa-2 cells treated with curcumin for 12 h and 24 h and were
determined by flow cytometry using propidium iodide staining for DNA content. Curcumin treatment significantly increased cells in the S and G2M
phase of cell cycle within 12 h. (B) Curcumin treatment induces apoptosis. MiaPaCa-2 and Pan02 cells incubated with 30 mM of curcumin were analyzed
for apoptosis by caspase 3/7 activation. Curcumin treatment increased the number of cells undergoing apoptosis compared to untreated controls
(*p,0.05). (Inset) Curcumin induces caspase 3, an apoptosis mediator. Lysates from MiaPaCa-2 or Pan02 cells incubated with 30mM curcumin were
analyzed by western blotting for caspase 3 protein. Curcumin treated cells shows cleaved (activated) caspase 3 while untreated cells have no cleaved
caspase-3. (C) Curcumin treatment increased the levels of cyclin B1, Cdc-2 and phosphorylated checkpoint kinase Chk2. Lysates from curcumin treated
MiaPaCa-2 cells (left) and Pan02 tumor xenografts (right) were analyzed by western blotting for phospho Chk2, and cyclin B1 and Cdc-2 protein
expression levels. Curcumin treatment phosphorylates checkpoint kinases andincreasedlevels of cyclinB1 andCdc-2in both MiaPaCa-2 cellsandPan02
tumor xenografts. (D) Curcumin treatment results in nuclear localization of cyclin B1 and Cdc-2. Immunocytochemistry of curcumin treated with
MiaPaCa-2 cells both the cyclinB1 and Cdc-2 protein levels were predominately in the nucleus compared than untreated cells. Phosphorylation of Chk2,
coupled with increased expression and nuclear translocation of cyclin B1 and Cdc-2 demonstrates mitotic progression of cells.
doi:10.1371/journal.pone.0016958.g003
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and thereby tumor growth [39]. VEGF mRNA and protein
expression was analyzed and was also found to be significantly lower
in curcumin treated tumor xenografts when compared to the control
tumors (Fig. 4A,B). Immunohistochemistry also demonstrated that
curcumin treatment significantly reduced the VEGF staining when
compared to control tumor (Fig. 4C). Cyclin D1 is a cell cycle
regulatory protein that regulates the G1 to S-phase transition and
functions as a cofactor for several transcription factors [40]. Cyclin
D1 overexpression has also been linked to the development and
progression of cancer [34]. Curcumin treatment inhibited cyclin D1
expression in the tumor xenografts suggesting that it inhibits cancer
cell proliferation (Fig. 4A,B). A number of RNA-binding proteins
have been identified to recognize ARE-containing sequences and
regulate mRNA stability. Members of the CELF (CUGBP2) and
ELAV (HuR) family of RNA binding proteins are implicated in
various cellular processes including mRNA splicing, editing, stability
and translation [23,41]. We have previously demonstrated that
CUGBP2 is induced in cells undergoing apoptosis and functions to
inhibit COX-2 mRNA translation [28,42]. T-cell- restricted
intracellular antigen-1 (TIA-1) is also an RNA binding protein that
functions as a translational suppressor, especially under conditions of
stress [43]. Here we observed that curcumin treatment resulted in a
significant increase in both CUGBP2 and TIA-1 mRNA and protein
expression in the tumor xenografts (Fig. 4A, B, D). On the other
hand, there was no significant change observed in both HuR mRNA
and protein levels in response to curcumin (Fig. 3A, B, D).
Curcumin inhibits COX-2 and VEGF mRNA translation in
pancreatic cancer cells
Previous studies have demonstrated increased levels of COX-2
mRNAand proteinexpressioninpancreaticadenocarcinomas[38].
Therefore, we nextdeterminedthe effects of curcumintreatment on
COX-2 expression. Curcumin treatment significantly increased
COX-2 mRNA levels in MiaPaCa-2 cells (Fig. 5A). However, there
was a significant reduction in COX-2 protein levels (Fig. 5B).
Similar results were observed on Pan02 cells (data not shown). We
also determined the effect of curcumin on VEGF gene expression in
the cells. Curcumin treatment significantly increased VEGF mRNA
while inhibiting protein levels in MiaPaCa-2 cells (Fig. 5A,B).
Similar results were observed in Pan02 cells (data not shown). On
the other hand, curcumin significantly increased both CUGBP2
and TIA-1 mRNA and protein expression (Fig. 5A,B). However,
there was no significant change observed with HuR expression
(Fig. 5A,B). In previous studies, we have demonstrated that
CUGBP2 binds to COX-2 39UTR to inhibit its translation [28].
Given that COX-2 mRNA levels are higher, but protein levels are
lower in response to curcumin treatment, we determined whether
curcumin increases the binding of CUGBP2 to COX-2 mRNA.
Immunoprecipitation coupled RT-PCR demonstrated that there
was a higher level of CUGBP2 binding to COX-2 and VEGF
mRNA when compared to control, untreated cells (Fig. 5C).
Furthermore, actinomycin D experiments demonstrated that
curcumin treatment resulted in significantly higher levels of
COX-2 mRNA stability, the half-life increasing from 30 min in
the untreated cells to ,8 h (Fig. 5D). Similar results were observed
with VEGF; the half-life of VEGF mRNA also increased from
30 min to .8 h in curcumin treated cells (Fig. 5D).
Curcumin mediated COX-2 and VEGF mRNA stability
requires CUGBP2
We have previously shown that CUGBP2 binding to COX-2
39UTR increases the stability of COX-2 mRNA, while inhibiting
its translation [28]. We therefore determined the effect of
CUGBP2 knockdown on curcumin-mediated translation suppres-
sion of COX-2 and VEGF mRNA. Real Time PCR measure-
ments demonstrated that curcumin treatment resulted in signifi-
cantly higher levels of COX-2 and VEGF mRNA, which was
reduced to control levels when CUGBP2 expression was
knockdown (Fig. 6A). We next determined if there were any
effects on protein expression. Curcumin treatment significantly
decreased the levels of both COX-2 and VEGF protein. However,
when CUGBP2 was knocked down with a specific siRNA, COX-2
and VEGF proteins levels were not affected by curcumin
treatment (Fig. 6B). We also determined whether curcumin-
mediated effects on COX-2 and VEGF mRNA stability are
affected by CUGBP2 knockdown. While curcumin treatment
increased the stability of COX-2 and VEGF mRNA, there was a
lesser effect when CUGBP2 was also knocked down using specific
siRNA. The half-life of COX-2 mRNA was increased from
30 min to ,8 h following curcumin treatment, which was reduced
to ,2 h when CUGBP2 expression was inhibited (Fig. 6C).
Similar results were obtained for VEGF where knockdown of
CUGBP2 reduced the curcumin-mediated stability from 8 h to
1 h (Fig. 6C). These data suggest that the curcumin mediated
increase in COX-2 and VEGF mRNA stability occurs in part
through CUGBP2.
Discussion
Pancreatic cancer is one of the most lethal cancers and has
emerged as one of the leading causes of cancer-related deaths in
the western world, with most patients dying of their disease with in
one year of diagnosis. The significant morbidity, toxicity and poor
response rates of current chemotherapy regimens have led to
searches for less toxic alternative therapies. Previous studies have
shown that curcumin suppresses the proliferation of a variety of
tumor cells, including pancreatic cancer [11,12,44,45]. Although
earlier studies have attributed the anti-tumor properties of
curcumin to the inhibition of COX-2 and VEGF expression, the
mechanism by which this occurs is not completely understood.
RNA binding protein HuR has been demonstrated to bind to the
COX-2 39UTR and enhance the stability and translation of
COX-2 mRNA [46]. In this case, we have demonstrated
CUGBP2 binds to the same sequence, but inhibits COX-2
mRNA translation [28]. Moreover, we have demonstrated that
CUGBP2 induces cells to undergo mitotic catastrophe. This
intrigued and inspired us to further investigate the role of these
RNA binding proteins in curcumin mediated pancreatic tumor
growth inhibition.
Our in vivo xenograft studies demonstrated that curcumin
treatment resulted in the downregulation of COX-2 and VEGF
proteins coupled with a reduction in microvessel density. In the
studies conducted with pancreatic cancer cells in culture, 2 h
following curcumin treatment there was an increase in the levels of
tumor promoting genes COX-2 and VEGF mRNA. However,
there was a significant reduction in the levels of both proteins
suggesting translation inhibition. A number of RNA binding
proteins have been identified that regulate the stability and
translation of AU-rich containing mRNAs. Here, we show that
curcumin increased the expression of two RNA binding proteins
CUGBP2 and TIA-1. Both proteins have been demonstrated to
inhibit translation of target mRNAs including COX-2 and VEGF
upon binding to the AU-rich sequences in the 39untranslated
region. Moreover, TIA-1 has been shown to bind untranslated
mRNAs and localize them into discrete cytoplasmic foci called
stress granules (SGs) [47,48]. These foci have been hypothesized to
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decisions are made on their subsequent engagement with the
translation or degradation machineries.
Previous studies have demonstrated that curcumin inhibits the
expression of COX-2 and VEGF [21,22]. Here, we performed a
time course for COX-2 and VEGF mRNA levels from 2 h to 24 h
Figure 4. Curcumin inhibits COX-2, VEGF and Cyclin D1 expression in the tumors while inducing CUGBP2 and TIA-1. (A) Total RNA
from Pan02 tumor xenografts were subjected to Real time PCR. Curcumin treatment resulted in reduced COX-2, VEGF and cyclin D1 mRNA levels
when compared to controls. On the other hand, CUGBP2 and TIA-1 mRNA expression was increased (*p,0.05). Data is an average from xenografts in
5 mice. (B) Western blot analysis demonstrated that tissue lysates from the curcumin treated animals have significantly lower levels of COX-2, VEGF,
and cyclin D1 proteins but increased levels of CUGBP2 and TIA-1 proteins. (C) Immunohistochemistry demonstrates that curcumin treatment
significantly reduced the expression of COX-2 and VEGF. (D) Immunohistochemistry demonstrates increased expression of CUGBP2 and TIA-1 in the
tumor xenografts.
doi:10.1371/journal.pone.0016958.g004
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increase up to 2-fold but decrease after 4h. We believe the cells
initially upregulate COX-2 and VEGF mRNA to counter the
effects of curcumin, but then CUGBP2 is also upregulated to
inhibit their translation.
We demonstrate that curcumin effectively inhibits the growth of
pancreatic tumor xenografts in part through the induction of
mitotic catastrophe. As such, mitotic catastrophe is a poorly
defined type of cell death linked to the abnormal activation of
cyclin B/Cdk1. This can occur at various steps during the G2M
phase of cell cycle. One form could occur with a significant delay
in the G2 checkpoint, while another occurs around metaphase in a
partially p53-dependent fashion. In this case, the cells die due to
caspase activation and mitochondrial membrane depolarization.
Figure 5. Curcumin inhibits COX-2 and VEGF protein expression in pancreatic cancer cells while inducing CUGBP2 and TIA-1. (A)
mRNA expression. MiaPaCa-2 cells were treated with curcumin for 2 h. Curcumin treatment increased the levels of COX-2, VEGF, CUGBP2 and TIA-1
mRNA. There was no significant change of HuR mRNA expression (* p,0.05). Data from three independent experiments. (B) Western blot analyses
demonstrate that lysates with curcumin treated MiaPaCa-2 cells have lower levels of COX-2 and VEGF proteins and increasing levels of CUGBP2 and
TIA-1. Representative of three independent experiments. (C) (Left panel), Increased binding of CUGBP2 binding to COX-2 or VEGF mRNA following
curcumin treatment. Whole cell extract (T) from curcumin-treated cells were immunoprecipitated with anti-CUGBP2 antibody, and RNA from the
immunoprecipitates (P) and supernatant (S) were isolated and subjected to RT-PCR for COX-2 and VEGF mRNA. Data demonstrates increased COX-2
or VEGF mRNA in the pellet of curcumin-treated cells. (Right panel) Data was quantified and there was a clear increase in COX-2 and VEGF mRNA in
the pellet of curcumin treated cells. (D) MiaPaCa-2 cells were treated with curcumin for 2 h and the stability of COX-2 and VEGF mRNA were
determined following addition of actinomycin D (final concentration: 10 mg/ml). Curcumin increases the half-life of COX-2 mRNA from 30 min to 8 h.
Similarly, curcumin increased the half-life of VEGF mRNA from 30 min to 8 h. Data demonstrates curcumin treatment significantly increased stability
of COX-2 or VEGF mRNA.
doi:10.1371/journal.pone.0016958.g005
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and VEGF mRNA levels. MiaPaCa-2 cells were transfected with CUGBP2 siRNA for 72 h and subsequently treated with curcumin for 2 h. Knockdown of
CUGBP2 significantly decreased curcumin-mediated increase in COX-2 and VEGF mRNA expression (*p,0.05). Data from three independent
experiments. (B) Western blot analyses of MiaPaCa-2 cell lysates demonstrate that knockdown of CUGBP2 partially restored the expression of COX-2
and VEGF proteins. (C) Knockdown of CUGBP2 reduces curcumin-induced stability of COX-2 and VEGF mRNA. MiaPaCa-2 cells were treated with
curcumin for 2 h and the stability of COX-2 and VEGF mRNA were determined following addition of actinomycin D (10 mg/ml). Curcumin increases
the half life of COX-2 and VEGF mRNA. However, knockdown of CUGBP2 using specific siRNA before curcumin treatment decreased the stability of
both COX-2 and VEGF mRNA.
doi:10.1371/journal.pone.0016958.g006
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cytogenic abnormalities thereby leading to oncogenesis. Our data,
demonstrating that curcumin induces mitotic catastrophe in part
through induction of CUGBP2 expression is consistent with this
observation. In previous studies, we have demonstrated that
CUGBP2 induces cancer cells to undergo mitotic catastrophe
when overexpressed. Further studies are necessary to determine
what percentage of pancreatic cancer cells can overcome
curcumin-induced apoptosis in the setting of CUGBP2 downreg-
ulation.
Our in vitro study results show that curcumin can effectively
suppress cell proliferation within 24 h. Moreover, the inhibitory
effects on tumor cells appears to be sustained and irreversible after
24 h of treatment. Our data with cyclin D1 is intriguing in that
there was a reduction in its expression at 24 h. This should have
resulted in cells undergoing G0–G1 arrest since the protein is
responsible for progression through the G0–G1/S phase transition
[40]. However, we believe this reduction is because the cells have
undergone G2M arrest at 24 h following curcumin and are not
actively progressing through the cell cycle. In addition, curcumin
downregulated the expression of cyclin A2, a protein that regulates
S-G2 progression, potentially slowing progression of cells out of S
phase. Further studies are required to determine if this is
compensatory mechanism from the cancer cells to protect from
mitotic catastrophe. Taken together, these data suggest that
curcumin can affect various stages of cell cycle progression of
pancreatic cancer cells, but the significant effect is the induction of
apoptosis during mitosis leading to mitotic catastrophe.
In conclusion, these studies provide mechanistic evidence that
curcumin mediated inhibition of COX-2 and VEGF expression
occurs through increased expression of RNA binding proteins
CUGBP2 and TIA-1 resulting in mitotic catastrophe of the tumor
cells. Considering that curcumin treated cells were actively
transiting through mitosis before undergoing mitotic catastrophe,
it further implies that inducing CUGBP2 and TIA-1 might be an
effective chemotherapeutic strategy to treat pancreatic cancer
cells. Moreover, the possibility exists that induction of these RNA
binding proteins might enhance the sensitivity to chemotherapeu-
tic agents, thereby reducing the bystander toxic effects of the
compounds on neighboring cells.
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